Literature DB >> 20686276

Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.

Masaki Miyamoto1, Noriaki Manabe, Ken Haruma.   

Abstract

BACKGROUND: Non-erosive reflux disease (NERD) is a more difficult to treat than reflux esophagitis (RE) due to the high prevalence of PPI resistance. Consequently, the treatment strategy for NERD is yet to be established. PATIENTS AND METHODS: Subjects were 467 GERD patients (NERD 349, RE 118, 47.4 +/- 16.7 years) with reflux symptoms such as heartburn. PPI was administered for 2 weeks, and total score (TS) of symptoms, seven items of reflux symptoms e.g. heartburn (reflux score: RS), and five items of dyspeptic symptoms e.g. heavy stomach (dyspeptic score: DS) were assessed using the frequency scale for the symptoms of GERD (FSSG), a GERD-specific questionnaire developed in Japan. Improvement <50% in TS was defined as non-responder. Patients' background, and pretreatment TS, RS, DS, and 12 items of FSSG were assessed. Furthermore, the effect of additional prokinetics (4 weeks) for 117 PPI non-response NERD patients was also examined.
RESULTS: Younger age, constipation, higher TS, DS, F2 (bloated stomach), 3 (heavy stomach), 5 (sick feeling after meal), 8 (satiety during meal) in FSSG were factors to be PPI non-responders in NERD. Significant improvement in TS were observed (pretreatment: 17.4 +/- 7.7 vs. 2 weeks 14.6 +/- 6.0 vs. 6 weeks 7.7 +/- 5.2, p<0.0001) after the addition of prokinetics in PPI non-response NERD.
CONCLUSION: Younger age, constipation, dysmotility were factors of PPI non-response in NERD. As high DS is correlated with PPI non-response, it is indicated that patients with strong dysmotility and functional dyspepsia complication might be PPI resistant. The efficacy of additional prokinetics for PPI non-response NERD was observed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686276     DOI: 10.2169/internalmedicine.49.3615

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  18 in total

Review 1.  Management of the patient with incomplete response to PPI therapy.

Authors:  Peter J Kahrilas; Guy Boeckxstaens; Andre J P M Smout
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-06       Impact factor: 3.043

Review 2.  Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review.

Authors:  Qing Liu; Chen-Chen Feng; Er-Man Wang; Xiu-Juan Yan; Sheng-Liang Chen
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

3.  Proton-pump inhibitors for the treatment of functional dyspepsia.

Authors:  Hidekazu Suzuki; Sawako Okada; Toshifumi Hibi
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

Review 4.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

Review 5.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.

Authors:  Katsuhiko Iwakiri; Yoshikazu Kinoshita; Yasuki Habu; Tadayuki Oshima; Noriaki Manabe; Yasuhiro Fujiwara; Akihito Nagahara; Osamu Kawamura; Ryuichi Iwakiri; Soji Ozawa; Kiyoshi Ashida; Shuichi Ohara; Hideyuki Kashiwagi; Kyoichi Adachi; Kazuhide Higuchi; Hiroto Miwa; Kazuma Fujimoto; Motoyasu Kusano; Yoshio Hoshihara; Tatsuyuki Kawano; Ken Haruma; Michio Hongo; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

Review 6.  Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.

Authors:  Li-Hua Ren; Wei-Xu Chen; Li-Juan Qian; Shuo Li; Min Gu; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

7.  Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.

Authors:  Nobuyuki Matsuhashi; Mineo Kudo; Norimasa Yoshida; Kazunari Murakami; Mototsugu Kato; Tsuyoshi Sanuki; Atsushi Oshio; Takashi Joh; Kazuhide Higuchi; Ken Haruma; Koji Nakada
Journal:  J Gastroenterol       Date:  2015-04-08       Impact factor: 7.527

8.  Effect of proton pump inhibition on acid, weakly acid and weakly alkaline gastro-esophageal reflux in children.

Authors:  Helena Turk; Bruno Hauser; Jernej Brecelj; Yvan Vandenplas; Rok Orel
Journal:  World J Pediatr       Date:  2013-02-07       Impact factor: 2.764

Review 9.  A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.

Authors:  L Hillman; R Yadlapati; A J Thuluvath; M A Berendsen; J E Pandolfino
Journal:  Dis Esophagus       Date:  2017-09-01       Impact factor: 3.429

10.  Lifestyle factors associated with gastroesophageal reflux disease in the Japanese population.

Authors:  Nobuyuki Matsuki; Tsuyoshi Fujita; Naoya Watanabe; Atsushi Sugahara; Akihiko Watanabe; Tsukasa Ishida; Yoshinori Morita; Masaru Yoshida; Hiromu Kutsumi; Takanobu Hayakumo; Hidekazu Mukai; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-08-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.